Disparities in the Early Adoption of Chemoimmunotherapy for Diffuse Large B-cell Lymphoma in the United States
Cancer Epidemiology, Biomarkers & Prevention, 08/17/2012
Flowers CR et al. – Black diffuse large B–cell lymphoma (DLBCL) patients were less likely to receive chemotherapy or chemoimmunotherapy during this period. This large national cohort study shows disparities in the diffusion of chemoimmunotherapy for DLBCL. Improving DLBCL outcomes will require efforts to extend access to proven advances in therapy to all segments of the population.